Isfahan University of Medical Sciences

Science Communicator Platform

Share By
Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients



Hosseini A1 ; Ghaedi K1, 2 ; Tanhaei S2 ; Ganjalikhanihakemi M3 ; Teimuri S1 ; Etemadifar M4 ; Esfahani MHN2
Authors

Source: Cell Journal Published:2016

Abstract

Objective: MicroRNAs (miRNA) are a class of non-coding RNAs which play key roles in post-transcriptional gene regulation. Previous studies indicate that miRNAs are dysregulated in patients with multiple sclerosis (MS). Th17 and regulatory T (Treg) cells are two subsets of CD4+ T-cells which have critical functions in the onset and progression of MS. The current study seeks to distinguish?uctuations in expression of CD4+ T-cell derived miR-223 during the relapsing-remitting (RR) phase of MS (RR-MS), as well as the expressions of Th17 and Treg cell markers. Materials and Methods: This experimental study used real-time quantitative polymerase chain reaction (qRT-PCR) to evaluate CD4+ T cell derived miR-223 expression patterns in patients that experienced either of the RR-MS phases (n=40) compared to healthy controls (n=12), along with RNA markers for Th17 and Treg cells. We conducted?ow cytometry analyses of forkhead box P3 (FOXP3) and RAR-related orphan receptor?t (ROR?t) in CD4+ T-cells. Putative and validated targets of miR-223 were investigated in the miRWalk and miRTarBase databases, respectively. Results: miR-223 signifcantly upregulated in CD4+ T-cells during the relapsing phase of RR-MS compared to the remitting phase (P=0.000) and healthy individuals (P=0.036). Expression of ROR?t, a master transcription factor of Th17, upregulated in the relapsing phase, whereas FOXP3 upregulated in the remitting phase. Additionally, potential targets of miR-223, STAT1, FORKHEAD BOX O (FOXO1) and FOXO3 were predicted by in silico studies. Conclusion: miR-223 may have a potential role in MS progression. Therefore, suppression of miR-223 can be proposed as an appropriate approach to control progression of the relapsing phase of MS.
Related Docs
View other Related Docs
1. Mir-141 and Mir-200A, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis, PLoS ONE (2015)
2. Analysis of the Expression of Mir-34A, Mir-199A, Mir-30C and Mir-19A in Peripheral Blood Cd4+T Lymphocytes of Relapsing-Remitting Multiple Sclerosis Patients, Gene (2018)
3. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
Experts (# of related papers)
View all Related Experts
Mohammadreza Sharifi (4)
Masoud Etemadifar (3)
Other Related Docs
4. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
5. Differential Expression Profile of Mir-27B, Mir-29A, and Mir-155 in Chronic Lymphocytic Leukemia and Breast Cancer Patients, Molecular Therapy Oncolytics (2020)
6. Mir-574, Mir-499, Mir-125B, Mir-106A, and Mir-9 Potentially Target Tgfbr-1 and Tgfbr-2 Genes Involving in Inflammatory Response Pathway: Potential Novel Biomarkers for Chronic Lymphocytic Leukemia, Pathology Research and Practice (2022)
7. Inducing Cell Proliferative Prevention in Human Acute Promyelocytic Leukemia by Mir-182 Inhibition Through Modulation of Casp9 Expression, Biomedicine and Pharmacotherapy (2017)
8. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
9. Microrna-92A Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis, Inflammation (2019)
10. Mir-196: Emerging of a New Potential Therapeutic Target and Biomarker in Colorectal Cancer, Molecular Biology Reports (2020)
11. Bioinformatics Prediction and Experimental Validation of a Novel Microrna: Hsa-Mir-B43 Within Human Cdh4 Gene With a Potential Metastasis-Related Function in Breast Cancer, Journal of Cellular Biochemistry (2020)
12. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
13. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
14. Degradation of Mir-21 Induces Apoptosis and Inhibits Cell Proliferation in Human Hepatocellular Carcinoma, Cancer Gene Therapy (2015)
15. Inhibition of Microrna Mir-222 With Lna Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia, Indian Journal of Hematology and Blood Transfusion (2017)
16. Therapeutic Inhibition of Microrna-21 (Mir-21) Using Locked-Nucleic Acid (Lna)-Anti-Mir and Its Effects on the Biological Behaviors of Melanoma Cancer Cells in Preclinical Studies, Cancer Cell International (2020)
17. Blockage of Mir-92A-3P With Locked Nucleic Acid Induces Apoptosis and Prevents Cell Proliferation in Human Acute Megakaryoblastic Leukemia, Cancer Gene Therapy (2016)
18. The Oncogene Musashi1 Encodes Novel Mirnas in Breast Cancer, Scientific Reports (2023)
19. Molecular Mechanisms of Mir-1236 in the Assessment of Tumor Lymphangiogenesis in Human Ovarian Cancer Patients, Journal of Gene Medicine (2023)
20. Glutathione Targeted Tragacanthic Acid-Chitosan As a Non-Viral Vector for Brain Delivery of Mirna-219A-5P: An in Vitro/In Vivo Study, International Journal of Biological Macromolecules (2022)